253 related articles for article (PubMed ID: 35725420)
1. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Zheng Q; Min S; Zhou Y
BMC Cancer; 2022 Jun; 22(1):674. PubMed ID: 35725420
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.
Fu ZZ; Li K; Peng Y; Zheng Y; Cao LY; Zhang YJ; Sun YM
Medicine (Baltimore); 2017 Jan; 96(2):e5853. PubMed ID: 28079819
[TBL] [Abstract][Full Text] [Related]
3. Short-Term Efficacy of Different First-Line Chemotherapy Regimens for Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Zhang BB; Zhu W; Tao J; Li Y; Du CC; Chen YX; Liu YD
Clin Transl Sci; 2020 May; 13(3):589-598. PubMed ID: 31961478
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis.
Liu T; He Z; Dang J; Li G
Radiat Oncol; 2019 Mar; 14(1):55. PubMed ID: 30925881
[TBL] [Abstract][Full Text] [Related]
5. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.
Liew MS; Sia J; Starmans MH; Tafreshi A; Harris S; Feigen M; White S; Zimet A; Lambin P; Boutros PC; Mitchell P; John T
Cancer Med; 2013 Dec; 2(6):916-24. PubMed ID: 24403265
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
[TBL] [Abstract][Full Text] [Related]
8. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
9. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
12. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel and Carboplatin
Su PH; Hsueh SW; Tseng CK; Ho MM; Su PJ; Hung CY; Yeh KY; Chang PH; Hung YS; Ho YW; Lin YC; Chou WC
In Vivo; 2021; 35(6):3391-3399. PubMed ID: 34697174
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
16. A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.
Li T; Yang F; Ma K; Lv L
Eur Arch Otorhinolaryngol; 2021 Sep; 278(9):3333-3344. PubMed ID: 33517538
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data.
Taniguchi Y; Okamoto H; Shimokawa T; Sasaki T; Seto T; Niho S; Ohe Y; Saigusa Y
BMC Pulm Med; 2022 Jan; 22(1):31. PubMed ID: 35000608
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer.
Akdeniz N; Küçüköner M; Kaplan MA; Urakçı Z; Karhan O; Sezgin Y; Bilen E; Ebinç S; Teke F; Laçin Ş; Alan Ö; Ercelep Ö; Işıkdoğan A; Yumuk PF
Int J Clin Oncol; 2020 Dec; 25(12):2015-2024. PubMed ID: 32797321
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis.
Lv Y; Cao Z; Pan J; Gong E; Zheng H; Cai X
Open Med (Wars); 2021; 16(1):183-191. PubMed ID: 33585694
[TBL] [Abstract][Full Text] [Related]
20. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
